tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NRSN Stock Latest News

NeuroSense Completes Data Collection for Alzheimer’s Trial
Company AnnouncementsNeuroSense Completes Data Collection for Alzheimer’s Trial
13d ago
6K
NRSN
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug
PremiumCompany Announcements
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug
17d ago
6K
NRSN
NeuroSense Gains FDA Approval for Phase 3 ALS Trial
PremiumCompany Announcements
NeuroSense Gains FDA Approval for Phase 3 ALS Trial
27d ago
6K
NRSN
NeuroSense reports FDA clearance to initiate Phase 3 trial for PrimeC in ALS
PremiumThe Fly
NeuroSense reports FDA clearance to initiate Phase 3 trial for PrimeC in ALS
27d ago
NRSN
NRSN Earnings this Week: How Will it Perform?
PremiumPre-Earnings
NRSN Earnings this Week: How Will it Perform?
28d ago
NRSN
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation
PremiumCompany AnnouncementsNeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation
1M ago
6K
NRSN
NeuroSense files to sell 333K ordinary shares for holders
Premium
The Fly
NeuroSense files to sell 333K ordinary shares for holders
2M ago
NRSN
NeuroSense initiated with an Outperform at Noble Capital
Premium
The Fly
NeuroSense initiated with an Outperform at Noble Capital
2M ago
NRSN
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC
PremiumCompany Announcements
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC
3M ago
6K
NRSN
NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study
PremiumThe Fly
NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study
3M ago
NRSN
NeuroSense Therapeutics Approves Resolutions at Annual Meeting
PremiumCompany Announcements
NeuroSense Therapeutics Approves Resolutions at Annual Meeting
3M ago
6K
NRSN
NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
PremiumCompany Announcements
NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
3M ago
6K
NRSN
NeuroSense Therapeutics Reports Promising Phase 2b Study Results for ALS Treatment
PremiumCompany AnnouncementsNeuroSense Therapeutics Reports Promising Phase 2b Study Results for ALS Treatment
4M ago
6K
NRSN
NeuroSense Therapeutics Secures $500,000 in Premium Private Placement
Premium
Company Announcements
NeuroSense Therapeutics Secures $500,000 in Premium Private Placement
4M ago
6K
NRSN
NeuroSense Therapeutics Announces Positive 18-Month Data for PrimeC in ALS Study
Premium
Company Announcements
NeuroSense Therapeutics Announces Positive 18-Month Data for PrimeC in ALS Study
4M ago
6K
NRSN
NeuroSense Therapeutics Announces Annual General Meeting for September 2025
PremiumCompany Announcements
NeuroSense Therapeutics Announces Annual General Meeting for September 2025
4M ago
6K
NRSN
NeuroSense Reports Long-Term Safety of PrimeC in ALS Study
PremiumCompany Announcements
NeuroSense Reports Long-Term Safety of PrimeC in ALS Study
4M ago
6K
NRSN
NeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeC
PremiumThe Fly
NeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeC
4M ago
NRSN
NeuroSense Therapeutics Advances ALS Treatment with Phase 3 Trial Plans
PremiumCompany Announcements
NeuroSense Therapeutics Advances ALS Treatment with Phase 3 Trial Plans
5M ago
6K
NRSN
NeuroSense Therapeutics Releases Q2 2025 Corporate Update
PremiumCompany AnnouncementsNeuroSense Therapeutics Releases Q2 2025 Corporate Update
5M ago
6K
NRSN
NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval
Premium
Company Announcements
NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval
6M ago
6K
NRSN
Target downgraded, Wayfair upgraded: Wall Street’s top analyst calls
Premium
The Fly
Target downgraded, Wayfair upgraded: Wall Street’s top analyst calls
7M ago
W
ON

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >